{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T10:54:07Z","timestamp":1792925647553,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,11,16]],"date-time":"2007-11-16T00:00:00Z","timestamp":1195171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s11239-007-0166-x","type":"journal-article","created":{"date-parts":[[2007,11,15]],"date-time":"2007-11-15T13:15:59Z","timestamp":1195132559000},"page":"204-206","source":"Crossref","is-referenced-by-count":9,"title":["Eptifibatide-induced thrombocytopenia"],"prefix":"10.1007","volume":"25","author":[{"given":"Marwan","family":"Refaat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J. Conrad","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Edmundowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,11,16]]},"reference":[{"issue":"1","key":"166_CR1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJM199001043220107","volume":"322","author":"BS Coller","year":"1990","unstructured":"Coller BS (1990) Platelets and thrombolytic therapy. N Engl J Med 322(1):33\u201342","journal-title":"N Engl J Med"},{"issue":"4745","key":"166_CR2","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.2420006","volume":"231","author":"R Pytela","year":"1986","unstructured":"Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E (1986) Platelet membrane glycoprotein IIb\/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 231(4745):1559\u20131562","journal-title":"Science"},{"issue":"6","key":"166_CR3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1997.03550060055036","volume":"278","author":"EJ Topol","year":"1997","unstructured":"Topol EJ, Ferguson JJ,Weisman HF, Tcheng JE, Ellis SG, Kleiman NS et al (1997) Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of platelet IIb\/IIIa inhibition for prevention of ischemic complication. JAMA 278(6):479\u2013484","journal-title":"JAMA"},{"issue":"7","key":"166_CR4","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","volume":"339","author":"The PURSUIT Trial Investigators","year":"1998","unstructured":"The PURSUIT Trial Investigators (1998) Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb\/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 339(7):436\u2013443","journal-title":"N Engl J Med"},{"issue":"15","key":"166_CR5","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1016\/S0021-9258(18)92826-7","volume":"266","author":"RM Carborough","year":"1991","unstructured":"Carborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM et al (1991) Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem 266(15):9359\u20139362","journal-title":"J Biol Chem"},{"issue":"8","key":"166_CR6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/hc3301.094533","volume":"104","author":"JE Tcheng","year":"2001","unstructured":"Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC et al (2001) Abciximab readministration: results of the ReoPro readministration registry. Circulation 104(8):870\u2013875","journal-title":"Circulation"},{"issue":"3","key":"166_CR7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/(SICI)1096-8652(199907)61:3<205::AID-AJH8>3.0.CO;2-9","volume":"61","author":"SJ Jubelirer","year":"1999","unstructured":"Jubelirer SJ, Koenig BA, Bates MC (1999) Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy. Am J Hematol 61(3):205\u2013208","journal-title":"Am J Hematol"},{"issue":"4","key":"166_CR8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.amjcard.2003.10.041","volume":"93","author":"IE Fahdi","year":"2004","unstructured":"Fahdi IE, Saucedo JF, Hennebry T, Ghani M, Sadanandan S, Garza-Arreola L (2004) Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention. Am J Cardiol 93(4):453\u2013455","journal-title":"Am J Cardiol"},{"issue":"25","key":"166_CR9","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","volume":"344","author":"EJ Topol","year":"2001","unstructured":"Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ et al (2001) Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344(25):1888\u20131894","journal-title":"N Engl J Med"},{"key":"166_CR10","doi-asserted-by":"crossref","unstructured":"The IMPACT-II Investigators (1997) Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimise platelet aggregation and coronary thrombosis-II. Lancet 349(9063):1422\u20131428","DOI":"10.1016\/S0140-6736(96)10172-0"},{"issue":"19","key":"166_CR11","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1001\/jama.285.19.2468","volume":"285","author":"JC O\u2019Shea","year":"2001","unstructured":"O\u2019Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM et al (2001) Platelet glycoprotein IIb\/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 285(19):2468\u20132473","journal-title":"JAMA"},{"key":"166_CR12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11239-006-8785-1","volume":"22","author":"S Epelman","year":"2006","unstructured":"Epelman S, Nair D, Downey R, Militello M, Askari A (2006) Eptifibatide-induced thrombocytopenia and thrombosis. J Thromb Thrombolysis 22:151\u2013154","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"166_CR13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ccd.10392","volume":"58","author":"SH Rezkalla","year":"2003","unstructured":"Rezkalla SH, Hayes JJ, Curtis BR, Aster RH (2003) Eptifibatide induced acute profound thrombocytopenia presenting as refractory hypotension. Catheter Cardiovasc Interv 58(1):76\u201379","journal-title":"Catheter Cardiovasc Interv"},{"issue":"2","key":"166_CR14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1345\/aph.1E244","volume":"39","author":"JC Coons","year":"2005","unstructured":"Coons JC, Barcelona RA, Freedy T, Hagerty MF (2005) Eptifibatide-associated acute, profound thrombocytopenia. Ann Pharmacother 39(2):368\u2013372","journal-title":"Ann Pharmacother"},{"issue":"1","key":"166_CR15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ccd.10390","volume":"58","author":"E Salengro","year":"2003","unstructured":"Salengro E, Mulvihill NT, Farah B (2003) Acute profound thrombocytopenia after use of eptifibatide for coronary stenting. Catheter Cardiovasc Interv 58(1):73\u201375","journal-title":"Catheter Cardiovasc Interv"},{"issue":"4","key":"166_CR16","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1345\/aph.1A218","volume":"36","author":"M Yoder","year":"2002","unstructured":"Yoder M, Edwards RF (2002) Reversible thrombocytopenia associated with eptifibatide. Ann Pharmacother 36(4):628\u2013630","journal-title":"Ann Pharmacother"},{"issue":"2","key":"166_CR17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1046\/j.1538-7836.2003.00056.x","volume":"1","author":"KA Tanaka","year":"2003","unstructured":"Tanaka KA, Vega JD, Kelly AB, Hanson SR, Levy JH (2003) Eptifibatide-induced thrombocytopenia and coronary bypass operation. J Thromb Haemost 1(2):392\u2013394","journal-title":"J Thromb Haemost"},{"issue":"3","key":"166_CR18","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1592\/phco.23.3.374.32107","volume":"23","author":"J Nagge","year":"2003","unstructured":"Nagge J, Jackevicius C, Dzavik V, Ross JR, Seidelin P (2003) Acute profound thrombocytopenia associated with eptifibatide therapy. Pharmacotherapy 23(3):374\u2013379","journal-title":"Pharmacotherapy"},{"issue":"7","key":"166_CR19","first-page":"797","volume":"19","author":"Y Khaykin","year":"2003","unstructured":"Khaykin Y, Paradiso-Hardy FL, Madan M (2003) Acute thrombocytopenia associated with eptifibatide therapy. Can J Cardiol 19(7):797\u2013801","journal-title":"Can J Cardiol"},{"issue":"6","key":"166_CR20","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1182\/blood.V100.6.2071","volume":"100","author":"DW Bougie","year":"2002","unstructured":"Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S et al (2002) Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb\/IIIa. Blood 100(6):2071\u20132076","journal-title":"Blood"},{"issue":"6","key":"166_CR21","first-page":"1095","volume":"84","author":"LK Jennings","year":"2000","unstructured":"Jennings LK, Haga JH, Slack SM (2000) Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb Haemost 84(6):1095\u20131102","journal-title":"Thromb Haemost"},{"issue":"4","key":"166_CR22","first-page":"674","volume":"92","author":"CP Hayward","year":"2004","unstructured":"Hayward CP (2004) Further complexities in diagnosing acquired thrombocytopenia: unexpected parallels between antibodymediated delayed thrombocytopenia with abciximab and heparin induced thrombocytopenia. Thromb Haemost 92(4):674\u2013675","journal-title":"Thromb Haemost"},{"issue":"6","key":"166_CR23","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1182\/blood.V99.6.2054","volume":"99","author":"BR Curtis","year":"2002","unstructured":"Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH (2002) Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 99(6):2054\u20132059","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-007-0166-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-007-0166-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-007-0166-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T20:23:19Z","timestamp":1630095799000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-007-0166-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,16]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["166"],"URL":"https:\/\/doi.org\/10.1007\/s11239-007-0166-x","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,16]]}}}